SCHEMBL246465

SCHEMBL246465

Cc1cc2nc(N3CCOCC3)ccc2c(-c2ccc(Cl)cc2)c1C(COC(=O)C(C)(C)C)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 5/20 0.39
HPGD P15428 4/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
TSHR P16473 3/20 0.38
GAA P10253 3/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
HSD17B10 Q99714 2/20 0.38
ALOX15 P16050 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MCHR1 Q99705 2/20 0.38
TDP1 Q9NUW8 2/20 0.36
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL246464 1.00 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDCYP1A2CYP2C19
SCHEMBL246463 1.00 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDCYP1A2CYP2C19
SCHEMBL27910442 0.89 MCHR1 (0.38) ALDH1A1KDM4EHPGDCYP1A2CYP2C19
SCHEMBL242742 0.88 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDCYP1A2CYP2C19
SCHEMBL242743 0.88 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDCYP1A2CYP2C19
SCHEMBL244906 0.84 NPC1 (0.37) KDM4EHPGDCYP1A2CYP2C19NPC1
SCHEMBL244904 0.84 NPC1 (0.37) KDM4EHPGDCYP1A2CYP2C19NPC1
SCHEMBL244905 0.84 NPC1 (0.37) KDM4EHPGDCYP1A2CYP2C19NPC1
SCHEMBL244816 0.84 PSIP1 (0.45) ALDH1A1KDM4EHPGDCYP1A2CYP2C19
SCHEMBL15182587 0.84 KMT2A (0.42) ALDH1A1KDM4EHPGDCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588455-B1 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2018-04-04 EP disclosed
US-9296758-B2 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds GILEAD SCIENCES, INC. (US) 2016-03-29 US disclosed
US-20130210801-A1 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-08-15 US disclosed
EP-2588455-A1 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2013-05-08 EP disclosed
WO-2012003498-A1 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210801-A1 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS NFATC1, ACIN1, ARF1 ALDH1A1 252/4885KDM4E 2264/4885HPGD 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.